Overview

Nebulized Heparin for COVID19-associated Acute Respiratory Failure

Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
The objective of the current study is to investigate the utilization of nebulized heparin to circumvent pathologic changes in COVID-19 and prevent harmful effects possible with systemic anticoagulation.
Phase:
Phase 2
Details
Lead Sponsor:
Brittany Bissell
University of Kentucky
Treatments:
Heparin